Related Experiment Video
Updated: May 24, 2026

09:01
Integrate Imaging Flow Cytometry and Transcriptomic Profiling to Evaluate Altered Endocytic CD1d Trafficking
Published on: October 29, 2018
Comparison of CD34-positive cells enumeration using ADAMII image-based fluorescence cell counter with fluorescence
Joan Cid1,2,3, Paola Charry1,2,3, María Dolores Herrera1
1Department of Hemotherapy and Hemostasis, ICAMS, Clínic Barcelona, Barcelona, Spain.
Clinical Chemistry and Laboratory Medicine
|May 22, 2026
Summary
Image-based CD34+ cell counting using the ADAMII device strongly correlates with flow cytometry. However, the ADAMII method showed lower counts in leukapheresis bags, necessitating further investigation for clinical accuracy.
Area of Science:
- Hematology
- Cell Biology
- Immunology
Background:
- CD34+ cell enumeration is crucial for stem cell transplantation.
- Fluorescence flow cytometry is the gold standard for CD34+ cell counting.
- Image-based methods offer potential alternatives for cell enumeration.
Purpose of the Study:
- To compare CD34+ cell counting between image-based (ADAMII) and fluorescence flow cytometry methods.
- To evaluate the accuracy and reliability of the ADAMII device for CD34+ cell enumeration.
Main Methods:
- Samples from mobilized peripheral blood (MPB) and leukapheresis bags (LB) were analyzed.
- CD34+ cells were enumerated using both flow cytometry (ISHAGE protocol) and the ADAMII device.
- Spearman rank correlation and Bland-Altman analysis were employed to assess agreement and bias.
Main Results:
- A strong positive linear correlation (rs>0.9, p<0.001) was found between ADAMII and flow cytometry.
- Flow cytometry yielded statistically higher CD34+ cell counts in LB samples.
- No statistically significant difference in counts was observed between methods for MPB samples.
Conclusions:
- The ADAMII device demonstrates strong correlation with flow cytometry for CD34+ cell counting.
- Discrepancies in LB samples suggest potential underestimation by the ADAMII device.
- Further research is needed to confirm ADAMII's clinical utility and avoid potential diagnostic errors.

